• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, Chief Comm. Officer Shiblaq Hisham sold $1,282,637 worth of shares (20,000 units at $64.13) and exercised 20,000 shares at a strike of $5.18 (SEC Form 4)

    6/6/25 4:02:37 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shiblaq Hisham

    (Last) (First) (Middle)
    C/O PROCEPT BIOROBOTICS CORPORATION
    150 BAYTECH DRIVE

    (Street)
    SAN JOSE CA 95134

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PROCEPT BioRobotics Corp [ PRCT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Chief Comm. Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    06/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/06/2025 M 20,000 A $5.18 83,133 D
    Common Stock 06/06/2025 S 12,296 D $63.7115(1) 70,837 D
    Common Stock 06/06/2025 S 5,904 D $64.6358(2) 64,933 D
    Common Stock 06/06/2025 S 1,800 D $65.3506(3) 63,133 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $5.18 06/06/2025 M 20,000 (4) 12/15/2030 Common Stock 20,000 $0 11,578 D
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.24 to $64.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
    2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.24 to $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
    3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.29 to $65.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
    4. The stock option is fully vested and exercisable.
    Remarks:
    /s/ Jonathan Stone, Attorney-in-Fact for Hisham Shiblaq 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRCT

    DatePrice TargetRatingAnalyst
    12/2/2024$105.00Overweight
    Morgan Stanley
    11/14/2024$95.00Hold
    Jefferies
    8/11/2023$42.00Overweight
    Piper Sandler
    5/31/2023Outperform
    William Blair
    10/31/2022Neutral
    BTIG Research
    10/25/2022$58.00Buy
    Truist
    9/2/2022$49.00Overweight
    Wells Fargo
    7/15/2022$47.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

      SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Wednesday, June 4 at 10am CT / 11am ET 2025 Jefferies Global Healthcare Conference Location – New York City, NYFireside Chat – Thursday, June 5 at 8:45m ET

      4/29/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

      Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT)  ("PROCEPT"), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada. Clinical data presentations will highlight long-term outcomes, safety and durability of Aquablation® therapy for BPH. Th

      4/24/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on PROCEPT BioRobotics with a new price target

      Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00

      12/2/24 7:01:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on PROCEPT BioRobotics with a new price target

      Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00

      11/14/24 8:28:45 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on PROCEPT BioRobotics with a new price target

      Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00

      8/11/23 7:19:06 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    SEC Filings

    See more
    • SEC Form 144 filed by PROCEPT BioRobotics Corporation

      144 - PROCEPT BioRobotics Corp (0001588978) (Subject)

      6/6/25 4:22:07 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

      10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

      5/2/25 4:51:16 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PROCEPT BioRobotics Corporation

      DEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:28:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Desai Antal Rohit sold $4,719,492 worth of shares (75,000 units at $62.93) and was granted 1,538 shares, increasing direct ownership by 22% to 8,403 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 7:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Director Moll Frederic H was granted 1,538 shares, increasing direct ownership by 0.18% to 843,159 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 4:27:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Director Sandoval Elisabeth was granted 1,538 shares, increasing direct ownership by 14% to 12,561 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 4:26:45 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care